Raymond James Financial Services Advisors’s Checkpoint Therapeutics CKPT Stock Holding History

Raymond James Financial Services Advisors’s Portfolio CKPT Stock Details CKPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	$23.7K	Hold	10,595	–	–	﹤0.01%	3393
2024 Q2	$22.8K	Hold	10,595	–	–	﹤0.01%	3340
2024 Q1	$21.7K	Buy	+10,595	New	+$21.1K	﹤0.01%	3339
2022 Q4	–	Sell	-8,256	Closed	-$86K	–	3287
2022 Q3	$86K	Buy	8,256 +873	+12%	+$10.4K	﹤0.01%	3018
2022 Q2	$76K	Buy	7,383 +4,283	+138%	+$56.1K	﹤0.01%	3052
2022 Q1	$55K	Hold	3,100	–	–	﹤0.01%	3185
2021 Q4	$96K	Buy	3,100 +200	+7%	+$6.62K	﹤0.01%	3127
2021 Q3	$96K	Buy	2,900 +872	+43%	+$25.8K	﹤0.01%	3123
2021 Q2	$60K	Buy	2,028 +112	+6%	+$3.1K	﹤0.01%	3194
2021 Q1	$60K	Buy	+1,916	New	+$64.2K	﹤0.01%	3086

Other funds holding CKPT

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

PAM

PVG Asset Management Golden, Colorado $173M AUM 64.51% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Raymond James Financial Services Advisors's CKPT Position: Q3 2024 in Review

Raymond James Financial Services Advisors held its Checkpoint Therapeutics (CKPT) position steady in Q3 2024 at 10,595 shares worth $23.7K. The position accounts for ﹤0.01% of the portfolio, ranked #3393.

Raymond James Financial Services Advisors first reported a position in CKPT in Q1 2021 and has held it in 10 quarters since. The position peaked at $96K in Q4 2021. 47 funds tracked by Wall St. Rank hold CKPT as of Q3 2024.

Raymond James Financial Services Advisors held 10,595 shares of Checkpoint Therapeutics worth $23.7K as of Q3 2024.
Raymond James Financial Services Advisors left its Checkpoint Therapeutics share count unchanged in Q3 2024.
Checkpoint Therapeutics made up ﹤0.01% of Raymond James Financial Services Advisors's portfolio in Q3 2024, its #3393 holding.
Raymond James Financial Services Advisors first reported a position in Checkpoint Therapeutics in Q1 2021 and has held it in 10 quarters since.
Raymond James Financial Services Advisors's Checkpoint Therapeutics position peaked at $96K in Q4 2021.
47 funds tracked by Wall St. Rank held Checkpoint Therapeutics as of Q3 2024.

Based on Raymond James Financial Services Advisors's 13F filing for Q3 2024, filed 18 Oct 2024.